Last updated: 2026-09-09 09:09:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
BioVie, Inc. (BIVI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.14, with a market capitalization of $16.90M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.82 to $3.79. This page covers its latest market performance, valuation, price trends and company information.
$16.90M | |
$2.09 | |
$4,609.77 | |
$0.82 | |
$2.07 | |
2.11K | |
4.62M | |
-- | |
$3.79 | |
$0.82 | |
-- | |
-- |
BioVie, Inc. (BIVI) is trading at $2.14 in pre-market trading as of 2026-09-09 08:54:00, up 3.38% ($0.07) from the previous close of $2.07
Pre-market trading shows how investors are pricing BIVI before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, BioVie, Inc. (BIVI) moved from $2.16 to $2.14, representing a decline of 0.93% ($0.02).
The stock traded between $1.96 and $2.49 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 558.74 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 44.4%
BIVI is currently trading at $2.14, placing it 44.4% of the way from its 52-week low of $0.82 to its 52-week high of $3.79. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 13 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BioVie, Inc. (BIVI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.